These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38477985)

  • 1. A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening.
    Chung DC; Gray DM; Singh H; Issaka RB; Raymond VM; Eagle C; Hu S; Chudova DI; Talasaz A; Greenson JK; Sinicrope FA; Gupta S; Grady WM
    N Engl J Med; 2024 Mar; 390(11):973-983. PubMed ID: 38477985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening.
    Imperiale TF; Porter K; Zella J; Gagrat ZD; Olson MC; Statz S; Garces J; Lavin PT; Aguilar H; Brinberg D; Berkelhammer C; Kisiel JB; Limburg PJ;
    N Engl J Med; 2024 Mar; 390(11):984-993. PubMed ID: 38477986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multitarget Stool RNA Test for Colorectal Cancer Screening.
    Barnell EK; Wurtzler EM; La Rocca J; Fitzgerald T; Petrone J; Hao Y; Kang Y; Holmes FL; Lieberman DA
    JAMA; 2023 Nov; 330(18):1760-1768. PubMed ID: 37870871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multitarget stool DNA testing for colorectal-cancer screening.
    Imperiale TF; Ransohoff DF; Itzkowitz SH; Levin TR; Lavin P; Lidgard GP; Ahlquist DA; Berger BM
    N Engl J Med; 2014 Apr; 370(14):1287-97. PubMed ID: 24645800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specificity of the Multi-Target Stool DNA Test for Colorectal Cancer Screening in Average-Risk 45-49 Year-Olds: A Cross-Sectional Study.
    Imperiale TF; Kisiel JB; Itzkowitz SH; Scheu B; Duimstra EK; Statz S; Berger BM; Limburg PJ
    Cancer Prev Res (Phila); 2021 Apr; 14(4):489-496. PubMed ID: 33436397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development and validation of predictive models for esophageal squamous cell carcinoma and its precancerous lesions using terminal motif analysis in circulating cell-free DNA].
    Liu SY; Li ZQ; Dou LZ; Zhang YM; Liu Y; Liu YM; Ke Y; Liu XD; Wu HR; Chu JT; He S; Wang GQ
    Zhonghua Zhong Liu Za Zhi; 2024 Jun; 46(6):549-565. PubMed ID: 38880735
    [No Abstract]   [Full Text] [Related]  

  • 7. Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals.
    Grobbee EJ; Wisse PHA; Schreuders EH; van Roon A; van Dam L; Zauber AG; Lansdorp-Vogelaar I; Bramer W; Berhane S; Deeks JJ; Steyerberg EW; van Leerdam ME; Spaander MC; Kuipers EJ
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD009276. PubMed ID: 35665911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylation of Septin9, SRSF1, and PAX8 in Early Screening of Colorectal Cancer in the Population Undergoing Physical Examinations.
    Li Q; Jiang W; Zhang Y; Yang X; Huang T; Huang Y; Yang S; Wang Q
    Clin Lab; 2023 Dec; 69(12):. PubMed ID: 38084698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colorectal cancer screening: comparison of transferrin and immuno fecal occult blood test.
    Chen JG; Cai J; Wu HL; Xu H; Zhang YX; Chen C; Wang Q; Xu J; Yuan XL
    World J Gastroenterol; 2012 Jun; 18(21):2682-8. PubMed ID: 22690078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-Year Interval for the Multi-Target Stool DNA Test for Colorectal Cancer Screening: A Longitudinal Study.
    Imperiale TF; Lavin PT; Marti TN; Jakubowski D; Itzkowitz SH; May FP; Limburg PJ; Sweetser S; Daghestani A; Berger BM
    Cancer Prev Res (Phila); 2023 Feb; 16(2):89-97. PubMed ID: 36205504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions.
    Tänzer M; Balluff B; Distler J; Hale K; Leodolter A; Röcken C; Molnar B; Schmid R; Lofton-Day C; Schuster T; Ebert MP
    PLoS One; 2010 Feb; 5(2):e9061. PubMed ID: 20140221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
    Sharma T
    Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new approach to epigenome-wide discovery of non-invasive methylation biomarkers for colorectal cancer screening in circulating cell-free DNA using pooled samples.
    Gallardo-Gómez M; Moran S; Páez de la Cadena M; Martínez-Zorzano VS; Rodríguez-Berrocal FJ; Rodríguez-Girondo M; Esteller M; Cubiella J; Bujanda L; Castells A; Balaguer F; Jover R; De Chiara L
    Clin Epigenetics; 2018; 10():53. PubMed ID: 29686738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients.
    Prince M; Lester L; Chiniwala R; Berger B
    World J Gastroenterol; 2017 Jan; 23(3):464-471. PubMed ID: 28210082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy comparison among high risk factors questionnaire and Asia-Pacific colorectal screening score and their combinations with fecal immunochemical test in screening advanced colorectal tumor].
    Zhu N; Huang YQ; Song YM; Zhang SZ; Zheng S; Yuan Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jul; 25(7):612-620. PubMed ID: 35844124
    [No Abstract]   [Full Text] [Related]  

  • 17. A novel screening method of DNA methylation biomarkers helps to improve the detection of colorectal cancer and precancerous lesions.
    Li Y; Li B; Jiang R; Liao L; Zheng C; Yuan J; Zeng L; Hu K; Zhang Y; Mei W; Hong Z; Xiao B; Kong L; Han K; Tang J; Jiang W; Pan Z; Zhang S; Ding P
    Cancer Med; 2023 Nov; 12(21):20626-20638. PubMed ID: 37881109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of faecal immunochemical test false-positive results using a signature based on faecal bacterial markers.
    Malagón M; Ramió-Pujol S; Serrano M; Serra-Pagès M; Amoedo J; Oliver L; Bahí A; Mas-de-Xaxars T; Torrealba L; Gilabert P; Miquel-Cusachs JO; García-Nimo L; Saló J; Guardiola J; Piñol V; Cubiella J; Castells A; Aldeguer X; Garcia-Gil J
    Aliment Pharmacol Ther; 2019 Jun; 49(11):1410-1420. PubMed ID: 31025420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial.
    Singal AG; Gupta S; Skinner CS; Ahn C; Santini NO; Agrawal D; Mayorga CA; Murphy C; Tiro JA; McCallister K; Sanders JM; Bishop WP; Loewen AC; Halm EA
    JAMA; 2017 Sep; 318(9):806-815. PubMed ID: 28873161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of Postcolonoscopy Colorectal Neoplasia by Multi-target Stool DNA.
    Ebner DW; Eckmann JD; Burger KN; Mahoney DW; Bering J; Kahn A; Rodriguez EA; Prichard DO; Wallace MB; Kane SV; Finney Rutten LJ; Gurudu SR; Kisiel JB
    Clin Transl Gastroenterol; 2021 Jun; 12(6):e00375. PubMed ID: 34140458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.